

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

CLEVIDIPIINE INJECTABLE EMULSION OBTAINS DRUG REGISTRATION APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Clevidipine Injectable Emulsion (50ml:25mg, 100ml:50mg) (the “**Product**”) developed by the Group, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

The Product is a dihydropyridine calcium channel blocker and belongs to the class of fast-acting intravenous antihypertensive drugs indicated for the treatment of patients with hypertension when oral therapy is not feasible or is anticipated to be ineffective. Compared to drugs commonly used in clinical practice, the Product demonstrates the following distinct advantages: a faster onset of action, enabling rapid, real-time, and precise blood pressure control; more suitable for patients with hepatic or renal dysfunction, with no dose adjustment required during administration; no need for dilution prior to administration, providing significant benefits for patients at risk of fluid overload.

The approval of the Product will further enrich the Group’s product pipeline in the therapeutic area of cardiovascular disease, enhance the Group’s competitiveness in this field, and is expected to address the unmet clinical needs for medications used in hypertensive emergencies.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 February 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.